Minimum Bio

MINIMUM’s flagship product is its Mercurious Platform, which is designed to create a new model for early stage drug discovery. The platform harnesses an antibody drug discovery platform and repurposes it for drug target discovery; combining advances in molecular biology, next generation sequencing and machine learning into a single integrated architecture for rapid and agnostic drug target discovery with the goal of accelerating the rate of drug development.

By bringing powerful phage display and computational approaches to drug target discovery and development – aiming to reduce time, cost and risk to programs - MINIMUM offers to potentially change the value curve for the trillion-dollar Pharma industry.

We are reimagining the process of discovering new drug targets and new drug modalities in potentially half the time, and at half the cost.

Sydney, New South Wales, Australia